Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Neurology

The Diagnostic Process: EMG and Antibodies

At a Glance

Lambert-Eaton myasthenic syndrome is diagnosed by combining symptoms with EMG and repetitive nerve stimulation, especially a low resting muscle signal and a marked increase after exercise, plus P/Q-type VGCC antibody testing. SOX1 results can guide cancer screening but cannot replace chest imaging.

Because LEMS is so rare, diagnosing it is like assembling a complex puzzle. No single test—not even a positive antibody test—is enough to confirm the diagnosis on its own [1]. Instead, your medical team must carefully correlate three things: your physical symptoms, the electrical “signals” in your muscles, and the presence of specific markers in your blood [2][3].

The Electrical Evidence: EMG and RNS

The most definitive way to identify LEMS is through Electrodiagnostic Testing, which includes Electromyography (EMG) and Repetitive Nerve Stimulation (RNS). This test measures how well your nerves communicate with your muscles.

In LEMS, the communication “switch” is stuck. The test typically looks for three specific electrical patterns:

  1. Low Resting Signal: When your muscle is at rest, the initial electrical response (called the Compound Muscle Action Potential or CMAP) is usually very small or “low” [4][5].
  2. The Drop-Off: When the nerve is stimulated slowly (2–5 times per second), the signal may get even weaker, a pattern called decrement [6].
  3. The “Big Jump” (Increment): This is the hallmark of LEMS. After you exercise the muscle for 10 seconds—or when the nerve is stimulated very rapidly—the muscle signal suddenly “wakes up” and grows much larger. A classic diagnostic criterion is an increase (increment) of greater than 100%. However, many modern protocols consider an increment of 60% or more to be strongly supportive of LEMS, depending on the baseline CMAP and the specific muscle tested [7][8].

It is important to know that an increment alone does not “confidently diagnose” LEMS; it must be interpreted alongside your clinical pattern and antibody results.

Blood Tests: Searching for Antibodies

Your doctor will order blood work to look for antibodies, which are the “attackers” in your immune system. Laboratory reports may use concentration units and specific reference ranges rather than a conventional “titer,” so you should review the actual value with your clinician.

  • P/Q-type VGCC Antibodies: These are found in approximately 85% to 90% of people with LEMS [9][2]. They are highly specific, meaning they aren’t usually found in healthy people. However, a minority of people with LEMS are seronegative, meaning they have the disease but don’t have these specific antibodies in their blood [10][11].
  • SOX1 Antibodies (Adjunctive Test): This is an optional, specialized test used to help estimate the risk of an underlying cancer. A positive result is strongly associated with an underlying small-cell lung cancer (SCLC) and should intensify the cancer search. However, a negative result does not rule out SCLC and does not replace the need for chest imaging [9][12].

Why Context Matters

Having a “positive” antibody result does not always mean you have LEMS. Low-level or moderate elevations of VGCC antibodies can sometimes appear in other neurological conditions or even without any clear disease at all [1][3].

Conversely, if your antibodies are negative but your EMG shows a classic low baseline CMAP with a massive increment after exercise, and you have classic leg weakness, your doctor can still diagnose seronegative LEMS [11][13].

Your Diagnostic Completeness Checklist

When reviewing your test results with your doctor, ensure your report includes these three key required elements:

  • [ ] Resting CMAP Amplitudes: Were they recorded as “low” before any exercise? [4]
  • [ ] Percentage of Increment: Did the signal increase significantly (e.g., >60% or >100%) after 10 seconds of exercise or high-frequency stimulation? [8]
  • [ ] P/Q-type VGCC Antibodies: Is the result positive based on the lab’s reference range? [14]

Common questions in this guide

What pattern can an EMG show in Lambert-Eaton syndrome?
EMG with repetitive nerve stimulation often shows a small muscle response at rest, sometimes a further drop with slow stimulation, and a much larger response after brief exercise or rapid stimulation. This pattern reflects impaired nerve-to-muscle communication and must be interpreted alongside symptoms and blood tests.
What does the increment percentage mean on an LEMS test?
The increment is the percentage increase in the muscle’s electrical response after exercise or rapid nerve stimulation. An increase greater than 100% is a classic criterion, while an increase of 60% or more may strongly support LEMS in some testing protocols; the meaning depends on the starting signal, muscle tested, and method. It does not confirm LEMS by itself.
Can I have LEMS if my P/Q-type VGCC antibodies are negative?
Yes. Most people with LEMS have P/Q-type VGCC antibodies, but a minority are seronegative. Doctors can still consider LEMS when symptoms and characteristic EMG findings fit, while ruling out other explanations.
What does a positive P/Q-type VGCC antibody result mean?
These antibodies are found in many people with LEMS and are uncommon in healthy people, so a clearly positive result can support the diagnosis. Low or moderate elevations can occur with other neurologic conditions or without a clear disease, so the result must be compared with the laboratory’s reference range and your clinical findings.
Why might my doctor order a SOX1 antibody test?
SOX1 is an additional blood test that helps estimate whether LEMS may be associated with small-cell lung cancer. A positive result should prompt careful cancer evaluation, but a negative result does not rule out small-cell lung cancer or replace chest imaging.
What information should I look for in my EMG report?
Ask whether the report lists resting muscle-signal measurements, the exact percentage increase after exercise or rapid stimulation, and the muscles tested. These details help your clinician judge whether the electrical pattern supports LEMS.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was the exact percentage of 'increment' shown on my EMG, and did it meet the diagnostic thresholds for LEMS?
  2. 2.Which specific muscles were tested during the nerve stimulation, and were the resting signals (CMAP) considered low?
  3. 3.Was my P/Q-type VGCC antibody result considered positive based on the laboratory's specific reference range?
  4. 4.If my SOX1 antibody test was positive, how does that influence our cancer screening plan?
  5. 5.Since a minority of LEMS patients are 'seronegative' (no antibodies), if my blood tests are negative, can we still confirm the diagnosis based on my EMG results?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Low specificity of voltage-gated calcium channel antibodies in Lambert-Eaton myasthenic syndrome: a call for caution.

    Di Lorenzo R, Mente K, Li J, et al.

    Journal of neurology 2018; (265(9)):2114-2119 doi:10.1007/s00415-018-8959-8.

    PMID: 29987589
  2. 2

    Lambert-Eaton Myasthenic syndrome: early diagnosis is key.

    Ivanovski T, Miralles F

    Degenerative neurological and neuromuscular disease 2019; (9()):27-37 doi:10.2147/DNND.S192588.

    PMID: 31191084
  3. 3

    [A case of myasthenia gravis with coexistence of anti-acetylcholine receptor antibodies and anti-P/Q-type VGCC antibodies].

    Takeda Y, Noda Y, Seike N, Ishihara H

    Rinsho shinkeigaku = Clinical neurology 2024; (64(4)):292-295 doi:10.5692/clinicalneurol.cn-001945.

    PMID: 38508730
  4. 4

    Distinguishing Features of the Repetitive Nerve Stimulation Test Between Lambert-Eaton Myasthenic Syndrome and Myasthenia Gravis, 50-Year Reappraisal.

    Oh SJ

    Journal of clinical neuromuscular disease 2017; (19(2)):66-75 doi:10.1097/CND.0000000000000190.

    PMID: 29189551
  5. 5

    Classically Described, Paradoxically Underrecognized: A Case of Proximal Weakness, Hyporeflexia/Areflexia, and Dysautonomia.

    Mirian A, Sharma AK, Nicolle MW

    American journal of physical medicine & rehabilitation 2021; (100(7)):e98-e100 doi:10.1097/PHM.0000000000001632.

    PMID: 33109907
  6. 6

    Lambert-Eaton myasthenia syndrome: specified description of a response pattern to low-frequency repetitive nerve stimulation.

    Zhou X, Wang Z, Zhu Y, et al.

    Journal of electromyography and kinesiology : official journal of the International Society of Electrophysiological Kinesiology 2020; (53()):102437 doi:10.1016/j.jelekin.2020.102437.

    PMID: 32554206
  7. 7

    Lowering the cutoff value for increment increases the sensitivity for the diagnosis of Lambert-Eaton myasthenic syndrome.

    Lipka AF, Titulaer MJ, Tannemaat MR, Verschuuren JJGM

    Muscle & nerve 2020; (62(1)):111-114 doi:10.1002/mus.26885.

    PMID: 32291768
  8. 8

    Neuromuscular junction disorders beyond myasthenia gravis.

    Oh SJ

    Current opinion in neurology 2021; (34(5)):648-657 doi:10.1097/WCO.0000000000000972.

    PMID: 34914667
  9. 9

    N-type voltage-gated calcium channel antibody testing lacks diagnostic value in Lambert-Eaton myasthenic syndrome.

    Arlt FA, Majed M, Wu J, et al.

    Journal of neuroimmunology 2025; (406()):578681 doi:10.1016/j.jneuroim.2025.578681.

    PMID: 40651295
  10. 10

    Simulations of active zone structure and function at mammalian NMJs predict that loss of calcium channels alone is not sufficient to replicate LEMS effects.

    Ginebaugh SP, Badawi Y, Laghaei R, et al.

    Journal of neurophysiology 2023; (129(5)):1259-1277 doi:10.1152/jn.00404.2022.

    PMID: 37073966
  11. 11

    [Seronegative nonparaneoplastic Lambert-Eaton myasthenic syndrome].

    Sanadze AG, Sidnev DV, Tumurov DA

    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 2017; (117(5)):77-80 doi:10.17116/jnevro20171175177-80.

    PMID: 28638036
  12. 12

    SOX1 antibody-related paraneoplastic neurological syndromes: clinical correlates and assessment of laboratory diagnostic techniques.

    Vabanesi M, Pinto AL, Vogrig A, et al.

    Journal of neurology 2023; (270(3)):1691-1701 doi:10.1007/s00415-022-11523-y.

    PMID: 36512064
  13. 13

    Lambert-Eaton myasthenic syndrome.

    Lipka AF, Verschuuren JJGM

    Handbook of clinical neurology 2024; (200()):307-325 doi:10.1016/B978-0-12-823912-4.00012-8.

    PMID: 38494285
  14. 14

    P/Q- and N-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments.

    Zalewski NL, Lennon VA, Lachance DH, et al.

    Muscle & nerve 2016; (54(2)):220-7 doi:10.1002/mus.25027.

    PMID: 26789908

This page explains EMG, nerve stimulation, and antibody testing for LEMS for informational purposes only and does not replace medical advice. Your clinician should interpret your results and determine the appropriate cancer-screening plan.

Get notified when new evidence is published on Lambert-Eaton myasthenic syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.